Skip to content

‘INTERventional POLypharmacy - Drug Interactions, Risks’ Study 1 - Bonn-specific approach

‘INTERventional POLypharmacy - Drug Interactions, Risks’ Study 1 - Bonn-specific approach - INTERPOLAR-BN

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00036757
Enrollment
1000
Registered
2025-07-14
Start date
2025-07-21
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medication-related problems

Interventions

Group 1: Hospitalized adult patients at German university hospitals who are (co-)managed by ward-based clinical pharmacists.

Sponsors

Uniklinikum Bonn
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged 18 years and older who are treated on wards with ward pharmacists involvement.

Exclusion criteria

Exclusion criteria: - Pediatric wards - Intensive care units (ICUs) - Maternity wards

Design outcomes

Primary

MeasureTime frame
The primary objective of INTERPOLAR-1-BN is to estimate, in a monocentric setting, the mean number of medication-related problems (MRPs) in hospitalized patients (cohort prevalence) as well as the resolution rate of identified MRPs in routine clinical care. The previous approach under "Usual Care" (number of manually documented MRPs) is about to be compared to the intervention phase, which incorporates IT-based support for pharmacists, including algorithmic MRP detection. During the intervention phase, the number of MRPs includes both manually documented MRPs and algorithmically detected MRPs classified as clinically relevant (such as absolute contraindications, identified using the drug-disease list developed within the study).

Secondary

MeasureTime frame
Furthermore, the following secondary evaluation objectives will be pursued: (1) Analysis of the profiles of detected MRPs (contraindications, missing medications, dosing errors, administration errors, adverse drug reactions); (2) Analysis of the profiles of resolved MRPs; (3) Predictability of MRPs (regression models); (4) Assessment of the effort required for the detection and resolution of MRPs in routine clinical care

Countries

Germany

Contacts

Public ContactKatharina Karsten Dafonte

Uniklinikum Bonn

Katharina.Karsten_Dafonte@ukbonn.de+49 228 287 14036

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026